First clinical data with a novel LPA mRNA targeting siRNA, new results showing inhibition of Lp(a) oxidation by eicosapentaenoic acid, and evidence of the impact of Lp(a) testing on initiation of lipid lowering therapies were among the Lp(a) research presentations attracting attention at the American College of Cardiology congress in New Orleans, USA (28-30 March […]
Phase 1 data for SRSD216, a novel siRNA targeting human LPA mRNA, suggest dose dependent and durable Lp(a) lowering, with good tolerability. Single subcutaneous doses of SRSD216 (100 mg, 300 mg, 600 mg) or placebo were administered to three cohorts of eight individuals with Lp(a) levels ≥75 nmol/L.
Lp(a)-enriched plasma undergoes increasingly rapid oxidation at elevated levels, with oxidation inhibited by eicosapentaenoic acid (EPA), irrespective of enrichment level. These are the findings from a study investigating lipid oxidation rates in increasingly enriched Lp(a) plasma and the potential antioxidant activity of EPA.
Lipid lowering therapy (LLT) is being initiated in about one in five patients found to have elevated Lp(a) and not previously prescribed these agents, an analysis of the TriNetX Database (2021-2026) has shown.
US Latino patients with atherosclerotic cardiovascular disease (ASCVD) are missing out on Lp(a) testing despite the fact that cardiovascular disease is the leading cause of death in this group. A retrospective cohort study compared Lp(a) testing in Latino and non-Latino patients using medical records from 87 US health systems and 1:1 nearest-neighbour greedy propensity score […]
Either serum or EDTA plasma samples can be used for Lp(a) measurement in clinical and epidemiological settings as there is a good correlation between test results, conclude Atherosclerosis Risk in Communities (ARIC) study investigators from their comparison of the two techniques.
